WHO ICTRP trial
The trial is designed to determine the safety and efficacy of ABP 501 compared…
EUCTR2013-000537-12-HU · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2013-000537-12-HU |
|---|---|
| Public title | The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis |
| Scientific title | A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis |
| Primary sponsor | Amgen Inc |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | France;Hungary;Canada;Poland;Australia;Germany |
| Conditions | Moderate to Severe Plaque Psoriasis MedDRA version: 16.1 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] |
| Interventions | Product Name: ABP 501 Product Code: ABP 501 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Not applicable CAS Number: 1446410-95-2 Current Sponsor code: ABP 501 Other descriptive name: Biosimilar… |
| Registration date | Mar 7, 2013 |
| Target size | 340 |
| Secondary IDs | 20120263 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: